Literature DB >> 35235026

Prognostic impact of Auer rods for cytoreductive chemotherapy and myeloablative allogeneic stem cell transplantation in adult patients with myelodysplastic syndrome with excess blasts-2.

Yi Wang1, Yaoyao Shen1,2, Jiaqian Qi1,2, Jia Chen1,2, Yang Xu1,2,3, Feng Chen1,2, Xiao Ma1, Miao Miao1, Shengli Xue1,2, Huiying Qiu1,2, Xiaowen Tang1,2,3, Yue Han1,2,3, Suning Chen1,2,3, Aining Sun1,2, Yanming Zhang4, Depei Wu5,6,7,8, Ying Wang9,10,11,12.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35235026     DOI： 10.1007/s00277-022-04808-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  13 in total

1.  Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.

Authors:  Ulrich Germing; Corinna Strupp; Andrea Kuendgen; Manuel Aivado; Aristoteles Giagounidis; Barbara Hildebrandt; Carlo Aul; Rainer Haas; Norbert Gattermann
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

2.  Induction, Bridging, or Straight Ahead: The Ongoing Dilemma of Allografting in Advanced Myelodysplastic Syndrome.

Authors:  Nicolaus Kröger
Journal:  Biol Blood Marrow Transplant       Date:  2019-06-20       Impact factor: 5.742

3.  Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.

Authors:  Thomas Schroeder; Nadija Wegener; Michael Lauseker; Christina Rautenberg; Kathrin Nachtkamp; Esther Schuler; Mustafa Kondakci; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Biol Blood Marrow Transplant       Date:  2019-03-15       Impact factor: 5.742

4.  Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia.

Authors:  Tongyan Meng; Jiaqian Qi; Yuanxin Zhu; Yang Xu; Feng Chen; Shengli Xue; Miao Miao; Suning Chen; Yue Han; Xiaowen Tang; Huiying Qiu; Aining Sun; Depei Wu; Ying Wang
Journal:  Hematol Oncol       Date:  2021-01-31       Impact factor: 5.271

5.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

6.  Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.

Authors:  Esther Schuler; Natalie Zadrozny; Sabine Blum; Thomas Schroeder; Corinna Strupp; Barbara Hildebrandt; Andrea Kündgen; Norbert Gattermann; Carlo Aul; Mustafa Kondakci; Guido Kobbe; Rainer Haas; Ulrich Germing
Journal:  Ann Hematol       Date:  2018-08-04       Impact factor: 3.673

Review 7.  Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.

Authors:  Guillermo Garcia-Manero; Kelly S Chien; Guillermo Montalban-Bravo
Journal:  Am J Hematol       Date:  2020-11       Impact factor: 10.047

8.  John Auer and Auer rods; controversies revisited.

Authors:  Yataro Yoshida; Shigeru Oguma; Hitotshi Ohno
Journal:  Leuk Res       Date:  2008-10-22       Impact factor: 3.156

9.  Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia.

Authors:  Huijun Huang; Tiejun Qin; Zefeng Xu; Zhongxun Shi; Bing Li; Lijuan Pan; Naibo Hu; Shiqiang Qu; Gang Huang; Robert P Gale; Zhijian Xiao
Journal:  Br J Haematol       Date:  2019-12-27       Impact factor: 8.615

10.  Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.

Authors:  Li Ye; Yanling Ren; Xinping Zhou; Chen Mei; Liya Ma; Xingnong Ye; Juying Wei; Weilai Xu; Haitao Meng; Wenbin Qian; Wenyuan Mai; Yinjun Lou; Gaixiang Xu; Jiejing Qian; Yejiang Lou; Yingwan Luo; Lili Xie; Peipei Lin; Chao Hu; Jie Jin; Hongyan Tong
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-20       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.